<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>APPROVED</status><version>v2</version><patient-age>65</patient-age><report-id>FR-AMGEN-FRACT2012079442</report-id><gender>female</gender><reactions><reaction>Purpura cutane</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>panitumumab</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>METHOTREXATE</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>VELBE</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>ADRIAMYCIN</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>CISPLATIN</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>LESCOL</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>ANTIINFECTIVES AND ANTISEPTICS FOR LOCAL ORAL</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>Transitional cell carcinoma</indication></indications><patient-age>65</patient-age><outcomes><outcome>Required Inpatient Hospitalization</outcome></outcomes><country>France</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>864732_123</messagenumb>
		<messagesenderidentifier>AMGENSAFETY</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20130125152705</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>3</safetyreportversion>
		<safetyreportid>FR-AMGEN-FRACT2012079442</safetyreportid>
		<primarysourcecountry>FR</primarysourcecountry>
		<occurcountry>FR</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2013-01-25</transmissiondate>
		<reporttype>2</reporttype>
		<serious code="1">Yes</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>1</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2012-12-06</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2013-01-23</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>FR-AMGEN-FRACT2012079442</companynumb>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>FR</reportercountry>
			<qualification code="1">Physician</qualification>
			<studyname>Unknown</studyname>
			<sponsorstudynumb>panitumumab study</sponsorstudynumb>
			<observestudytype>1</observestudytype>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>AMGENSAFETY</senderorganization>
			<senderdepartment>Amgen Global Safety</senderdepartment>
			<sendergivename>Paul</sendergivename>
			<senderfamilyname>Eisenberg</senderfamilyname>
			<senderstreetaddress>One Amgen Center Drive</senderstreetaddress>
			<sendercity>Thousand Oaks</sendercity>
			<senderstate>California</senderstate>
			<senderpostcode>91320</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>8054471000</sendertel>
			<sendertelcountrycode>1</sendertelcountrycode>
			<senderfax>8054994495</senderfax>
			<senderfaxcountrycode>1</senderfaxcountrycode>
			<senderemailaddress>dsstriage@amgen.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receivergivename>Bill</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receivercountrycode>US</receivercountrycode>
			<receiveremailaddress>wtaylor@oc.fda.gov</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>PRIVACY</patientinitial>
			<patientbirthdateformat>102</patientbirthdateformat>
			<patientbirthdate>19470719</patientbirthdate>
			<patientonsetage>65</patientonsetage>
			<patientonsetageunit>801</patientonsetageunit>
			<patientagegroup>6</patientagegroup>
			<patientweight>55</patientweight>
			<patientheight>167</patientheight>
			<patientsex code="2">Female</patientsex>
			<resultstestsprocedures>Unknown date -  Urine culture: Negative.
Proteinuria: 0.37g/24h
22/Nov/2012 - Chest X-ray: no signs to support the presence of Wegener's granulomatosis.</resultstestsprocedures>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Bladder cancer</patientepisodename>
				<patientmedicalstartdateformat>602</patientmedicalstartdateformat>
				<patientmedicalstartdate>2011</patientmedicalstartdate>
				<patientmedicalcontinue>1</patientmedicalcontinue>
				<patientmedicalcomment>Bricker urinary diversion</patientmedicalcomment>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Metastases to liver</patientepisodename>
				<patientmedicalcontinue>1</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Metastases to lymph nodes</patientepisodename>
				<patientmedicalcontinue>1</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Epistaxis</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Bronchitis</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Stomatitis</patientepisodename>
				<patientmedicalcontinue>1</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Hypercholesterolaemia</patientepisodename>
				<patientmedicalcontinue>1</patientmedicalcontinue>
				<patientmedicalcomment>treated with Lescol</patientmedicalcomment>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Ex-tobacco user</patientepisodename>
				<patientmedicalcomment>10 cigarettes per day for 30 years until June 2010</patientmedicalcomment>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Breast cancer</patientepisodename>
				<patientmedicalstartdateformat>602</patientmedicalstartdateformat>
				<patientmedicalstartdate>1999</patientmedicalstartdate>
				<patientmedicalcontinue>1</patientmedicalcontinue>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Breast lump removal</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Radiotherapy</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Urinary cystectomy</patientepisodename>
				<patientmedicalstartdateformat>102</patientmedicalstartdateformat>
				<patientmedicalstartdate>20100825</patientmedicalstartdate>
				<patientmedicalcontinue>2</patientmedicalcontinue>
				<patientmedicalenddateformat>102</patientmedicalenddateformat>
				<patientmedicalenddate>20100825</patientmedicalenddate>
				<patientmedicalcomment>Cystectomy</patientmedicalcomment>
			</medicalhistoryepisode>
			<patientpastdrugtherapy>
				<patientdrugname>GEMZAR</patientdrugname>
				<patientdrugstartdateformat>610</patientdrugstartdateformat>
				<patientdrugstartdate>201010</patientdrugstartdate>
				<patientdrugenddateformat>610</patientdrugenddateformat>
				<patientdrugenddate>201101</patientdrugenddate>
				<patientindicationmeddraversion>15.1</patientindicationmeddraversion>
				<patientdrugindication>Bladder cancer</patientdrugindication>
			</patientpastdrugtherapy>
			<patientpastdrugtherapy>
				<patientdrugname>CISPLATINE</patientdrugname>
				<patientdrugstartdateformat>610</patientdrugstartdateformat>
				<patientdrugstartdate>201010</patientdrugstartdate>
				<patientdrugenddateformat>610</patientdrugenddateformat>
				<patientdrugenddate>201101</patientdrugenddate>
				<patientindicationmeddraversion>15.1</patientindicationmeddraversion>
				<patientdrugindication>Bladder cancer</patientdrugindication>
			</patientpastdrugtherapy>
			<reaction>
				<primarysourcereaction>Purpura cutane</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Purpura</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Purpura</reactionmeddrapt>
				<termhighlighted>3</termhighlighted>
				<reactionstartdateformat>102</reactionstartdateformat>
				<reactionstartdate>20121122</reactionstartdate>
				<reactionenddateformat>102</reactionenddateformat>
				<reactionenddate>20121214</reactionenddate>
				<reactionduration>22</reactionduration>
				<reactiondurationunit>804</reactiondurationunit>
				<reactionfirsttime>15</reactionfirsttime>
				<reactionfirsttimeunit>804</reactionfirsttimeunit>
				<reactionlasttime>13</reactionlasttime>
				<reactionlasttimeunit>804</reactionlasttimeunit>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121122</testdate>
				<testname>Alanine aminotransferase</testname>
				<testresult>13</testresult>
				<testunit>IU/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121130</testdate>
				<testname>Alanine aminotransferase</testname>
				<testresult>10</testresult>
				<testunit>IU/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121122</testdate>
				<testname>Aspartate aminotransferase</testname>
				<testresult>10</testresult>
				<testunit>IU/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121130</testdate>
				<testname>Aspartate aminotransferase</testname>
				<testresult>20</testresult>
				<testunit>IU/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121123</testdate>
				<testname>Biopsy</testname>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121122</testdate>
				<testname>Albumin</testname>
				<testresult>35</testresult>
				<testunit>g/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121130</testdate>
				<testname>Albumin</testname>
				<testresult>37</testresult>
				<testunit>g/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121122</testdate>
				<testname>Alkaline phosphatase</testname>
				<testresult>94</testresult>
				<testunit>IU/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121130</testdate>
				<testname>Alkaline phosphatase</testname>
				<testresult>71</testresult>
				<testunit>IU/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121122</testdate>
				<testname>Bilirubin</testname>
				<testresult>4</testresult>
				<testunit>습mol/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121130</testdate>
				<testname>Bilirubin</testname>
				<testresult>8</testresult>
				<testunit>습mol/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121122</testdate>
				<testname>Calcium</testname>
				<testresult>2.22</testresult>
				<testunit>mmol/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121130</testdate>
				<testname>Calcium</testname>
				<testresult>2.33</testresult>
				<testunit>mmol/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testname>Creatinine</testname>
				<testresult>52</testresult>
				<testunit>습mol/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121122</testdate>
				<testname>Creatinine</testname>
				<testresult>83</testresult>
				<testunit>습mol/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121130</testdate>
				<testname>Creatinine</testname>
				<testresult>82</testresult>
				<testunit>습mol/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121122</testdate>
				<testname>Folate</testname>
				<testresult>8.6</testresult>
				<testunit>mmol/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121122</testdate>
				<testname>Iron</testname>
				<testresult>12.2</testresult>
				<testunit>습mol/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121122</testdate>
				<testname>LDH</testname>
				<testresult>180</testresult>
				<testunit>IU/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121130</testdate>
				<testname>LDH</testname>
				<testresult>168</testresult>
				<testunit>IU/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121122</testdate>
				<testname>Potassium</testname>
				<testresult>3.9</testresult>
				<testunit>mmol/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121130</testdate>
				<testname>Potassium</testname>
				<testresult>4.7</testresult>
				<testunit>mmol/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121122</testdate>
				<testname>Sodium</testname>
				<testresult>134</testresult>
				<testunit>mmol/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121130</testdate>
				<testname>Sodium</testname>
				<testresult>138</testresult>
				<testunit>mmol/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121122</testdate>
				<testname>Urea</testname>
				<testresult>3.7</testresult>
				<testunit>mmol/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121130</testdate>
				<testname>Urea</testname>
				<testresult>5.2</testresult>
				<testunit>mmol/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testname>Chest X-ray</testname>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testname>Urine culture</testname>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121122</testdate>
				<testname>GGT</testname>
				<testresult>30</testresult>
				<testunit>IU/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121130</testdate>
				<testname>GGT</testname>
				<testresult>17</testresult>
				<testunit>IU/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121122</testdate>
				<testname>Hemoglobin</testname>
				<testresult>9.1</testresult>
				<testunit>g/dL</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121130</testdate>
				<testname>Hemoglobin</testname>
				<testresult>10.1</testresult>
				<testunit>g/dL</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121122</testdate>
				<testname>Platelet count</testname>
				<testresult>251000</testresult>
				<testunit>/mm^3</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121130</testdate>
				<testname>Platelet count</testname>
				<testresult>431000</testresult>
				<testunit>/mm^3</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121122</testdate>
				<testname>Protein</testname>
				<testresult>69</testresult>
				<testunit>g/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121130</testdate>
				<testname>Protein</testname>
				<testresult>69</testresult>
				<testunit>g/l</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121122</testdate>
				<testname>Serum ferritin</testname>
				<testresult>553</testresult>
				<testunit>ng/mL</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121122</testdate>
				<testname>Transferrin</testname>
				<testresult>16.7</testresult>
				<testunit>%</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121122</testdate>
				<testname>Vitamin B12</testname>
				<testresult>2440</testresult>
				<testunit>pmol/L</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121122</testdate>
				<testname>Leukocyte count NOS</testname>
				<testresult>17800</testresult>
				<testunit>/mm^3</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121130</testdate>
				<testname>Leukocyte count NOS</testname>
				<testresult>9200</testresult>
				<testunit>/mm^3</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121122</testdate>
				<testname>Polymorphonuclear count</testname>
				<testresult>14000</testresult>
				<testunit>/mm^3</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<test>
				<testdateformat>102</testdateformat>
				<testdate>20121130</testdate>
				<testname>Polymorphonuclear count</testname>
				<testresult>8500</testresult>
				<testunit>/mm^3</testunit>
				<moreinformation>2</moreinformation>
			</test>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>panitumumab</medicinalproduct>
				<obtaindrugcountry>FR</obtaindrugcountry>
				<drugauthorizationnumb>125-147</drugauthorizationnumb>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugauthorizationholder>Amgen</drugauthorizationholder>
				<drugstructuredosagenumb>300</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugdosagetext>300 mg, UNK</drugdosagetext>
				<drugdosageform normalized="solution for injection">Solution for injection</drugdosageform>
				<drugadministrationroute code="042">Intravenous (not otherwise specified)</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Transitional cell carcinoma</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2012-11-07</drugstartdate>
				<drugstartperiod>15</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<druglastperiod>13</druglastperiod>
				<druglastperiodunit>804</druglastperiodunit>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>2012-11-09</drugenddate>
				<drugtreatmentduration>3</drugtreatmentduration>
				<drugtreatmentdurationunit code="804">Day</drugtreatmentdurationunit>
				<actiondrug code="1">Drug Withdrawn</actiondrug>
				<activesubstance>
					<activesubstancename>panitumumab</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Purpura</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Purpura</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugresult>Yes</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>METHOTREXATE</medicinalproduct>
				<drugstructuredosagenumb>46</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugdosagetext>46 mg, UNK</drugdosagetext>
				<drugadministrationroute code="042">Intravenous (not otherwise specified)</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Transitional cell carcinoma</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2012-09-26</drugstartdate>
				<drugstartperiod>57</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<activesubstance>
					<activesubstancename>METHOTREXATE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>VELBE</medicinalproduct>
				<drugstructuredosagenumb>4.6</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugdosagetext>4.6 mg, UNK</drugdosagetext>
				<drugadministrationroute code="042">Intravenous (not otherwise specified)</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Transitional cell carcinoma</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2012-11-07</drugstartdate>
				<drugstartperiod>15</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<druglastperiod>13</druglastperiod>
				<druglastperiodunit>804</druglastperiodunit>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>2012-11-09</drugenddate>
				<drugtreatmentduration>3</drugtreatmentduration>
				<drugtreatmentdurationunit code="804">Day</drugtreatmentdurationunit>
				<activesubstance>
					<activesubstancename>VINBLASTINE SULFATE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>ADRIAMYCIN</medicinalproduct>
				<drugstructuredosagenumb>46</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugdosagetext>46 mg, UNK</drugdosagetext>
				<drugadministrationroute code="042">Intravenous (not otherwise specified)</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Transitional cell carcinoma</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2012-11-07</drugstartdate>
				<drugstartperiod>15</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<druglastperiod>13</druglastperiod>
				<druglastperiodunit>804</druglastperiodunit>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>2012-11-09</drugenddate>
				<drugtreatmentduration>3</drugtreatmentduration>
				<drugtreatmentdurationunit code="804">Day</drugtreatmentdurationunit>
				<activesubstance>
					<activesubstancename>DOXORUBICIN</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>CISPLATIN</medicinalproduct>
				<drugstructuredosagenumb>110</drugstructuredosagenumb>
				<drugstructuredosageunit code="003">milligrams</drugstructuredosageunit>
				<drugdosagetext>110 mg, UNK</drugdosagetext>
				<drugadministrationroute code="042">Intravenous (not otherwise specified)</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Transitional cell carcinoma</drugindication>
				<drugstartdateformat>102</drugstartdateformat>
				<drugstartdate>2012-11-06</drugstartdate>
				<drugstartperiod>16</drugstartperiod>
				<drugstartperiodunit>804</drugstartperiodunit>
				<druglastperiod>13</druglastperiod>
				<druglastperiodunit>804</druglastperiodunit>
				<drugenddateformat>102</drugenddateformat>
				<drugenddate>2012-11-09</drugenddate>
				<drugtreatmentduration>4</drugtreatmentduration>
				<drugtreatmentdurationunit code="804">Day</drugtreatmentdurationunit>
				<activesubstance>
					<activesubstancename>CISPLATIN</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>LESCOL</medicinalproduct>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugdosagetext>UNK</drugdosagetext>
				<activesubstance>
					<activesubstancename>FLUVASTATIN SODIUM</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>ANTIINFECTIVES AND ANTISEPTICS FOR LOCAL ORAL</medicinalproduct>
			</drug>
			<summary>
				<narrativeincludeclinical>The following event was received from an Investigator Sponsored Study (ISS)This <Semaphore x="1387834" class="Patient Age" value="65" score="1.00" ID=""><Semaphore x="5960701642276865" class="Patient Age" value="65" score="1.00" ID="">65 </Semaphore>year old </Semaphore>female was participating in an intensified <Semaphore x="861252" class="Medicine" value="Methotrexate" score="0.97" ID="279493">methotrexate</Semaphore>, <Semaphore x="1330202" class="Medicine" value="vinBLAStine" score="0.87" ID="196804">vinblastine</Semaphore>, <Semaphore x="507241" class="Medicine" value="DOXOrubicin" score="0.87" ID="259834">doxorubicin </Semaphore>and <Semaphore x="363530" class="Medicine" value="Cisplatin" score="0.98" ID="251595">cisplatin </Semaphore>(I MVAC) with or without <Semaphore x="978477" class="Medicine" value="panitumumab" score="1.00" ID="252216">panitumumab </Semaphore>as <Semaphore x="1938562" class="Procedure" value="First-Line Therapy" score="1.00" ID="C45792">first line treatment </Semaphore>of advanced <Semaphore x="2673497" class="Disease or Finding" value="Urothelial Carcinoma" score="1.00" ID="C4030">urothelial carcinoma </Semaphore>in patients without H Ras or <Semaphore x="2417537" class="Procedure" value="Potassium Measurement" score="1.00" ID="C64853">K </Semaphore>Ras <Semaphore x="2248448" class="Procedure" value="Mutation Analysis" score="1.00" ID="C18302">mutations </Semaphore>randomized phase III study and developed <Semaphore x="2439896" class="Disease or Finding" value="Purpura" score="1.00" ID="C78787">purpura </Semaphore>cutane.The subject's medical history included <Semaphore x="1598845" class="Disease or Finding" value="Bladder Carcinoma" score="1.00" ID="C4912">bladder carcinoma </Semaphore><Semaphore x="1846062" class="Procedure" value="Diagnosis" score="1.00" ID="C15220">diagnosed </Semaphore>in 2011 with <Semaphore x="2223099" class="Disease or Finding" value="Metastatic Malignant Neoplasm to the Lymph Node" score="1.00" ID="C4904"><Semaphore x="2223048" class="Disease or Finding" value="Metastatic Malignant Neoplasm to the Liver" score="1.00" ID="C4758"><Semaphore x="3108419" class="MedDRA LLT" value="Metastasis" score="1.00" ID="10062194">metastases </Semaphore>to liver </Semaphore>and lymph nodes</Semaphore>, Bricker <Semaphore x="2671712" class="Procedure" value="Urinary Diversion" score="1.00" ID="C91841">urinary diversion</Semaphore>, episodes of <Semaphore x="1892716" class="Disease or Finding" value="Epistaxis" score="1.00" ID="C26766">epistaxis</Semaphore>, <Semaphore x="1650011" class="Disease or Finding" value="Bronchitis" score="1.00" ID="C2911">bronchitis</Semaphore>, <Semaphore x="2587064" class="Disease or Finding" value="Stomatitis" score="1.00" ID="C26887">oral mucositis</Semaphore>, <Semaphore x="2036179" class="Disease or Finding" value="Hypercholesterolemia" score="1.00" ID="C37967">hypercholesterolemia</Semaphore>, smoking (10 cigarettes per day for 30 years until June 2010)<Semaphore x="1637909" class="Disease or Finding" value="Breast Carcinoma" score="1.00" ID="C4872">, and <Semaphore x="2826913" class="MedDRA LLT" value="Breast cancer" score="1.00" ID="10006187"><Semaphore x="1644502" class="AnatomicStructure" value="Breast Part" score="1.00" ID="C13020">breast </Semaphore>cancer </Semaphore></Semaphore>treated with <Semaphore x="2126838" class="Procedure" value="Lumpectomy" score="1.00" ID="C15755">lumpectomy </Semaphore>and <Semaphore x="2442569" class="Procedure" value="Radiation Therapy" score="1.00" ID="C15313">radiotherapy </Semaphore>(no supplement <Semaphore x="2032177" class="Disease or Finding" value="Hormone-Resistant Breast Cancer" score="1.00" ID="C114932">hormone </Semaphore>or <Semaphore x="1760803" class="Procedure" value="Chemotherapy" score="1.00" ID="C15632">chemotherapy</Semaphore>). The subject did not have relevant family history. Previous <Semaphore x="2065652" class="Procedure" value="Intervention or Procedure" score="0.58" ID="C25218">treatment </Semaphore>for the condition under study included an unspecified <Semaphore x="2065652" class="Procedure" value="Intervention or Procedure" score="0.58" ID="C25218">surgery </Semaphore>and <Semaphore x="1760803" class="Procedure" value="Chemotherapy" score="1.00" ID="C15632">chemotherapy</Semaphore>. Concomitant medications included <Semaphore x="778129" class="Medicine" value="Lescol" score="0.74" ID="239560">Lescol </Semaphore>(<Semaphore x="587291" class="Medicine" value="Fluvastatin sodium" score="0.74" ID="281861">fluvastatin <Semaphore x="2536895" class="Procedure" value="Sodium Measurement" score="1.00" ID="C64809">sodium</Semaphore></Semaphore>) and "mouthwash".The subject received the first dose of <Semaphore x="978477" class="Medicine" value="panitumumab" score="1.00" ID="252216">panitumumab </Semaphore>in combination with <Semaphore x="861252" class="Medicine" value="Methotrexate" score="0.97" ID="279493">methotrexate</Semaphore>, Velbe (<Semaphore x="1330202" class="Medicine" value="vinBLAStine" score="0.87" ID="196804">vinblastine</Semaphore>), <Semaphore x="47317" class="Medicine" value="Adriamycin" score="0.87" ID="268083">Adriamycin </Semaphore>(<Semaphore x="507241" class="Medicine" value="DOXOrubicin" score="0.87" ID="259834">doxorubicin</Semaphore>) and <Semaphore x="363530" class="Medicine" value="Cisplatin" score="0.98" ID="251595">cisplatin </Semaphore>on 06/Nov/2012. Approximately two weeks later, on 22/Nov/2012, the subject was hospitalized to receive the fifth course of study <Semaphore x="1760803" class="Procedure" value="Chemotherapy" score="1.00" ID="C15632">chemotherapy</Semaphore>. Reportedly, between cycles the subject had developed <Semaphore x="2027225" class="Procedure" value="Histopathologic Examination" score="1.00" ID="C18190">grade </Semaphore>I <Semaphore x="1550618" class="Disease or Finding" value="Asthenia" score="1.00" ID="C28132">asthenia </Semaphore>for seven days, <Semaphore x="2027225" class="Procedure" value="Histopathologic Examination" score="1.00" ID="C18190">grade </Semaphore>I <Semaphore x="2693861" class="Disease or Finding" value="Vomiting" score="1.00" ID="C3442">vomiting</Semaphore>, prolonged <Semaphore x="2027225" class="Procedure" value="Histopathologic Examination" score="1.00" ID="C18190">grade </Semaphore>III <Semaphore x="2243803" class="Disease or Finding" value="Mucositis" score="1.00" ID="C3853">mucositis </Semaphore>with significant ulceration for 10 days, slight <Semaphore x="1854566" class="Disease or Finding" value="Disease Response" score="1.00" ID="C50995">response </Semaphore>to Triflucan (<Semaphore x="580928" class="Medicine" value="Fluconazole" score="0.74" ID="268742">fluconazole</Semaphore>) and a non recurrent episode of <Semaphore x="2014051" class="Disease or Finding" value="Hematuria" score="1.00" ID="C3090">hematuria </Semaphore>on 18/Nov/2012 apparently synchronous with the onset of <Semaphore x="2439896" class="Disease or Finding" value="Purpura" score="1.00" ID="C78787">purpura </Semaphore>on the <Semaphore x="2104605" class="AnatomicStructure" value="Leg" score="1.00" ID="C32974">legs</Semaphore>. The subject did not develop <Semaphore x="2262749" class="Disease or Finding" value="Nausea" score="1.00" ID="C3258">nausea</Semaphore>, <Semaphore x="2974091" class="MedDRA LLT" value="Gastrointestinal toxicity" score="1.00" ID="10059024">gastrointestinal <Semaphore x="2638558" class="Disease or Finding" value="Toxicity" score="1.00" ID="C27990">toxicity</Semaphore></Semaphore>, hematological <Semaphore x="2638558" class="Disease or Finding" value="Toxicity" score="1.00" ID="C27990">toxicity</Semaphore>, <Semaphore x="2377148" class="Disease or Finding" value="Paresthesia" score="1.00" ID="C28177">paresthesia</Semaphore>, <Semaphore x="2353023" class="Disease or Finding" value="Ototoxicity" score="1.00" ID="C66929">ototoxicity </Semaphore>or <Semaphore x="2365183" class="Disease or Finding" value="Pain" score="1.00" ID="C3303">pain</Semaphore>. A <Semaphore x="2889895" class="MedDRA LLT" value="Culture urine negative" score="1.00" ID="10011639"><Semaphore x="2673030" class="AnatomicStructure" value="Urine" score="1.00" ID="C13283">urine </Semaphore>culture was <Semaphore x="2265745" class="Disease or Finding" value="Negative Patch Test" score="1.00" ID="C35633">negative</Semaphore></Semaphore>. Reportedly, the subject who had a Bricker <Semaphore x="2671712" class="Procedure" value="Urinary Diversion" score="1.00" ID="C91841">urinary diversion </Semaphore>had presented an episode of <Semaphore x="2014051" class="Disease or Finding" value="Hematuria" score="1.00" ID="C3090">hematuria </Semaphore>associated with infiltrated <Semaphore x="2439896" class="Disease or Finding" value="Purpura" score="1.00" ID="C78787">purpura</Semaphore>. Previous <Semaphore x="2406620" class="Procedure" value="Platelet Count" score="1.00" ID="C51951"><Semaphore x="2406620" class="Procedure" value="Platelet Count" score="1.00" ID="C51951">platelet </Semaphore>counts </Semaphore>from last month and at the day of examination did not revealed <Semaphore x="2614406" class="Disease or Finding" value="Thrombocytopenia" score="1.00" ID="C3408">thrombocytopenia</Semaphore>. The subject also had history of episodes of <Semaphore x="1892716" class="Disease or Finding" value="Epistaxis" score="1.00" ID="C26766">epistaxis </Semaphore>for two weeks and <Semaphore x="1650011" class="Disease or Finding" value="Bronchitis" score="1.00" ID="C2911">bronchitis </Semaphore>for two months.On admission, <Semaphore x="2397639" class="Procedure" value="Physical Examination" score="1.00" ID="C20989">physical examination </Semaphore>revealed <Semaphore x="2027225" class="Procedure" value="Histopathologic Examination" score="1.00" ID="C18190">grade </Semaphore>II <Semaphore x="2587064" class="Disease or Finding" value="Stomatitis" score="1.00" ID="C26887">oral mucositis </Semaphore>with sores, <Semaphore x="3238978" class="MedDRA LLT" value="Scab" score="1.00" ID="10039509">scabs </Semaphore>and microvesicles on the <Semaphore x="2116170" class="AnatomicStructure" value="Lip" score="1.00" ID="C12220">lips</Semaphore>, <Semaphore x="2393503" class="Disease or Finding" value="Petechia" score="1.00" ID="C3323">petechiae </Semaphore>of the <Semaphore x="2537040" class="AnatomicStructure" value="Soft Palate" score="1.00" ID="C12231">soft palate </Semaphore>and <Semaphore x="2107425" class="Disease or Finding" value="Lesion" score="1.00" ID="C3824">lesions </Semaphore>suggestive of either healing <Semaphore x="3262865" class="MedDRA LLT" value="Stomatitis" score="1.00" ID="10042128"><Semaphore x="2587064" class="Disease or Finding" value="Stomatitis" score="1.00" ID="C26887">mucositis or <Semaphore x="2338326" class="Disease or Finding" value="Oral Lichen Planus" score="1.00" ID="C7406">oral </Semaphore></Semaphore>
     <Semaphore x="3158643" class="MedDRA LLT" value="Oral lichen planus" score="1.00" ID="10030983">
      </Semaphore></Semaphore>
    <Semaphore x="3158643" class="MedDRA LLT" value="Oral lichen planus" score="1.00" ID="10030983">
     <Semaphore x="2338326" class="Disease or Finding" value="Oral Lichen Planus" score="1.00" ID="C7406">lichen planus </Semaphore></Semaphore>and infiltrated <Semaphore x="2439896" class="Disease or Finding" value="Purpura" score="1.00" ID="C78787">purpura </Semaphore>on the front of her <Semaphore x="2104605" class="AnatomicStructure" value="Leg" score="1.00" ID="C32974">legs</Semaphore>. No other <Semaphore x="2525335" class="Procedure" value="Skin Biopsy" score="1.00" ID="C51692">skin </Semaphore><Semaphore x="2107425" class="Disease or Finding" value="Lesion" score="1.00" ID="C3824">lesions</Semaphore>, particularly no folliculitis associated with <Semaphore x="978477" class="Medicine" value="panitumumab" score="1.00" ID="252216">panitumumab </Semaphore>were found. The subject remained afebrile. Additional <Semaphore x="3186740" class="MedDRA LLT" value="Physical examination normal" score="1.00" ID="10062079"><Semaphore x="2397639" class="Procedure" value="Physical Examination" score="1.00" ID="C20989">physical examination </Semaphore>was normal</Semaphore>. The subject's general state of health was good. <Semaphore x="3057951" class="MedDRA LLT" value="Laboratory test" score="1.00" ID="10059938">Laboratory tests </Semaphore>revealed <Semaphore x="2110173" class="Procedure" value="Leukocyte Count" score="1.00" ID="C51948">leukocyte </Semaphore><Semaphore x="3321117" class="MedDRA LLT" value="White blood cell count" score="1.00" ID="10047939">count </Semaphore>
    <Semaphore x="3321117" class="MedDRA LLT" value="White blood cell count" score="1.00" ID="10047939">of 17800/mm3, <Semaphore x="3321117" class="MedDRA LLT" value="White blood cell count" score="1.00" ID="10047939">polymorphonuclear </Semaphore>count </Semaphore>of 14000/mm3, <Semaphore x="2014841" class="Procedure" value="Hemoglobin Measurement" score="1.00" ID="C64848">hemoglobin </Semaphore>of 9.1 g/dL, <Semaphore x="2406620" class="Procedure" value="Platelet Count" score="1.00" ID="C51951"><Semaphore x="2406620" class="Procedure" value="Platelet Count" score="1.00" ID="C51951">platelet </Semaphore>count </Semaphore>of 251000/mm3, <Semaphore x="1821896" class="Procedure" value="Creatinine Measurement" score="1.00" ID="C64547">creatinine </Semaphore>of 83 umol/L, <Semaphore x="1316129" class="Medicine" value="Urea" score="0.74" ID="194669">urea </Semaphore>at 3.7 mmol/L, <Semaphore x="2536895" class="Procedure" value="Sodium Measurement" score="1.00" ID="C64809">sodium </Semaphore>of 134 mmol/L, <Semaphore x="1848940" class="Procedure" value="Dietary Protocol" score="1.00" ID="C93051">potassium </Semaphore>of 3.9 mmol/L, <Semaphore x="287292" class="Medicine" value="Calcium" score="0.74" ID="240008">calcium </Semaphore>at 2.22 mmol/L, <Semaphore x="2433448" class="Procedure" value="Protein or Enzyme Type Measurement" score="0.90" ID="C64430">protein </Semaphore>of 69 g/L, <Semaphore x="1470367" class="Procedure" value="Alkaline Phosphatase Measurement" score="1.00" ID="C64432">alkaline phosphatase </Semaphore>of 94 IU/L, <Semaphore x="1549211" class="Procedure" value="Aspartate Aminotransferase Measurement" score="1.00" ID="C64467">aspartate aminotransferase </Semaphore>of 10 IU/L, <Semaphore x="1469106" class="Procedure" value="Alanine Aminotransferase Measurement" score="1.00" ID="C64433">alanine aminotransferase </Semaphore>of 13 IU/L, and <Semaphore x="2967535" class="MedDRA LLT" value="Gamma-glutamyltransferase" score="1.00" ID="10017687">gamma glutamyltransferase </Semaphore>of 30 IU/L, <Semaphore x="2118991" class="Procedure" value="Liver Function Test" score="0.76" ID="C74954">total bilirubin </Semaphore>of 4 umol/l, <Semaphore x="2092491" class="Procedure" value="Lactate Dehydrogenase Measurement" score="1.00" ID="C64855"><Semaphore x="766926" class="Medicine" value="Lactate" score="0.74" ID="196905">lactate </Semaphore>dehydrogenase </Semaphore>of 180 IU/L, <Semaphore x="1469401" class="Procedure" value="Albumin Measurement" score="1.00" ID="C64431">albumin </Semaphore>of 35 g/L, <Semaphore x="744254" class="Medicine" value="Iron" score="0.49" ID="297813">iron </Semaphore>of 12.2 umol/l, ferritin of 553 ng/mL, folates of 8.6 mmol/L, <Semaphore x="2692070" class="Procedure" value="Vitamin B12 Measurement" score="1.00" ID="C64817">vitamin B12 </Semaphore>at 2440 pmol/l, and transferring saturation coefficient of 16.7%. There was improvement in renal function after hydration (<Semaphore x="1821896" class="Procedure" value="Creatinine Measurement" score="1.00" ID="C64547">creatinine </Semaphore>of 52 umol/L) and 24-h <Semaphore x="2433825" class="Disease or Finding" value="Proteinuria" score="1.00" ID="C38012">proteinuria </Semaphore>was 0.37 g/24 h. The latest <Semaphore x="1761285" class="Procedure" value="Chest Radiography" score="1.00" ID="C38103">chest x ray </Semaphore>performed showed no signs to support the presence of <Semaphore x="2697892" class="Disease or Finding" value="Wegener Granulomatosis" score="1.00" ID="C3444">Wegener's granulomatosis</Semaphore>.The investigator's <Semaphore x="2397639" class="Procedure" value="Physical Examination" score="1.00" ID="C20989">assessment </Semaphore>was probable <Semaphore x="2439896" class="Disease or Finding" value="Purpura" score="1.00" ID="C78787">vascular purpura</Semaphore>, however certain criteria <Semaphore x="2592399" class="Race" value="Sugpiaq" score="1.00" ID="C44488">suggested </Semaphore><Semaphore x="2614406" class="Disease or Finding" value="Thrombocytopenia" score="1.00" ID="C3408">thrombocytopenia</Semaphore>. <Semaphore x="1593910" class="Procedure" value="Biopsy" score="1.00" ID="C15189">Biopsy </Semaphore>with <Semaphore x="3006985" class="MedDRA LLT" value="Histology" score="1.00" ID="10062005">histology </Semaphore>and IF, <Semaphore x="1854919" class="Procedure" value="Disease Screening" score="1.00" ID="C15419">screens </Semaphore>for <Semaphore x="2053299" class="Disease or Finding" value="Infectious Disorder" score="1.00" ID="C26726">infectious and <Semaphore x="1557778" class="Disease or Finding" value="Autoimmune Disease" score="1.00" ID="C2889">autoimmune diseases </Semaphore></Semaphore>and measures of <Semaphore x="2692262" class="Procedure" value="Vitamin C Measurement" score="1.00" ID="C74903">vitamin C </Semaphore>concentrations would be performed to eliminate <Semaphore x="2502015" class="Disease or Finding" value="Scurvy" score="1.00" ID="C35010">scurvy</Semaphore>. <Semaphore x="2692262" class="Procedure" value="Vitamin C Measurement" score="1.00" ID="C74903">Vitamin C </Semaphore><Semaphore x="2326755" class="Procedure" value="Nutritional Supplementation" score="1.00" ID="C15425">supplementation </Semaphore>was <Semaphore x="2592399" class="Race" value="Sugpiaq" score="1.00" ID="C44488">suggested</Semaphore>. The <Semaphore x="1843527" class="Occupation" value="Dermatologist" score="1.00" ID="C17816">dermatologists </Semaphore>opinion was probable microvascularity. On 23/Nov/2012, <Semaphore x="1593910" class="Procedure" value="Biopsy" score="1.00" ID="C15189">skin biopsy </Semaphore>was done however <Semaphore x="1910095" class="Disease or Finding" value="Experimental Result" score="1.00" ID="C76125">result </Semaphore>were not provided at the time of this report. Immunological <Semaphore x="1854919" class="Procedure" value="Disease Screening" score="1.00" ID="C15419">screen </Semaphore>was requested with <Semaphore x="1549600" class="Procedure" value="Assay" score="1.00" ID="C60819">assay </Semaphore>of anti neutrophil <Semaphore x="1834765" class="Disease or Finding" value="Cytoplasm Presence of Less than or Equal to Twenty Five Percent" score="1.00" ID="C104013">cytoplasmic </Semaphore><Semaphore x="2047985" class="Procedure" value="Immunology Test" score="0.58" ID="C16723">antibody (<Semaphore x="2751745" class="MedDRA LLT" value="Antineutrophil cytoplasmic antibody" score="1.00" ID="10050552">ANCA</Semaphore>), anti streptolysin O </Semaphore>(ASLO), <Semaphore x="1531531" class="Procedure" value="Anti-DNA Antibody Measurement" score="1.00" ID="C81973">anti <Semaphore x="2751991" class="MedDRA LLT" value="Antinuclear antibody" score="1.00" ID="10002807">nuclear <Semaphore x="1531531" class="Procedure" value="Anti-DNA Antibody Measurement" score="1.00" ID="C81973">antibodies</Semaphore></Semaphore>
        <Semaphore x="2912242" class="MedDRA LLT" value="DNA antibody" score="1.00" ID="10061131">
         <Semaphore x="2047985" class="Procedure" value="Immunology Test" score="0.58" ID="C16723">
          <Semaphore x="1531531" class="Procedure" value="Anti-DNA Antibody Measurement" score="1.00" ID="C81973">, <Semaphore x="1531531" class="Procedure" value="Anti-DNA Antibody Measurement" score="1.00" ID="C81973">anti DNA </Semaphore></Semaphore></Semaphore></Semaphore>antibodies</Semaphore>, <Semaphore x="2886478" class="MedDRA LLT" value="Cryoglobulinaemia" score="1.00" ID="10011474">cryoglobulinaemia</Semaphore>, C3, C4, CHso, <Semaphore x="3234162" class="MedDRA LLT" value="Rheumatoid factor" score="1.00" ID="10039079"><Semaphore x="2469227" class="Procedure" value="Rheumatoid Factor Measurement" score="1.00" ID="C74717"><Semaphore x="2047985" class="Procedure" value="Immunology Test" score="0.58" ID="C16723">rheumatoid <Semaphore x="2751991" class="MedDRA LLT" value="Antinuclear antibody" score="1.00" ID="10002807">factor</Semaphore></Semaphore>
      </Semaphore>
     </Semaphore>
    <Semaphore x="2751991" class="MedDRA LLT" value="Antinuclear antibody" score="1.00" ID="10002807">, antinuclear factor </Semaphore>as well as <Semaphore x="2020151" class="Disease or Finding" value="Hepatitis C Infection" score="1.00" ID="C3098"><Semaphore x="2019803" class="Disease or Finding" value="Hepatitis B Infection" score="1.00" ID="C3097">hepatitis B </Semaphore>and C</Semaphore>.The subject was discharged from the hospital on 26/Nov/2012. The event was reported as ongoing at the time of discharge. <Semaphore x="2065652" class="Procedure" value="Intervention or Procedure" score="0.58" ID="C25218">Treatment </Semaphore>at discharge for various symptoms causing <Semaphore x="1854131" class="Disease or Finding" value="Discomfort" score="1.00" ID="C50535">discomfort </Semaphore>included <Semaphore x="778129" class="Medicine" value="Lescol" score="0.74" ID="239560">Lescol </Semaphore>(<Semaphore x="587291" class="Medicine" value="Fluvastatin sodium" score="0.74" ID="281861">fluvastatin <Semaphore x="2536895" class="Procedure" value="Sodium Measurement" score="1.00" ID="C64809">sodium</Semaphore></Semaphore>), Triflucan (<Semaphore x="580928" class="Medicine" value="Fluconazole" score="0.74" ID="268742">fluconazole</Semaphore>) and Fortimel (<Semaphore x="2433448" class="Procedure" value="Protein or Enzyme Type Measurement" score="0.90" ID="C64430">proteins</Semaphore>) and <Semaphore x="1386475" class="Medicine" value="Zovirax" score="0.49" ID="239608">Zovirax </Semaphore>(aciclovir) for probable <Semaphore x="3158561" class="MedDRA LLT" value="Oral herpes" score="1.00" ID="10067152">herpetic <Semaphore x="2587064" class="Disease or Finding" value="Stomatitis" score="1.00" ID="C26887">stomatitis</Semaphore></Semaphore>.Four days later, on 30/Nov/2012, the subject was re hospitalized for the fifth course of study <Semaphore x="1760803" class="Procedure" value="Chemotherapy" score="1.00" ID="C15632">chemotherapy</Semaphore>. <Semaphore x="2397639" class="Procedure" value="Physical Examination" score="1.00" ID="C20989">Physical examination </Semaphore>revealed <Semaphore x="2027225" class="Procedure" value="Histopathologic Examination" score="1.00" ID="C18190">grade </Semaphore>I <Semaphore x="2587064" class="Disease or Finding" value="Stomatitis" score="1.00" ID="C26887">oral mucositis </Semaphore>and <Semaphore x="2439896" class="Disease or Finding" value="Purpura" score="1.00" ID="C78787">purpura </Semaphore>on the front of both <Semaphore x="2104605" class="AnatomicStructure" value="Leg" score="1.00" ID="C32974">legs </Semaphore>which was less infiltrated <Semaphore x="1803212" class="Procedure" value="Comparison of Screening Methods" score="1.00" ID="C62743">compared </Semaphore>to the examination on 22/Nov/2012. <Semaphore x="3057951" class="MedDRA LLT" value="Laboratory test" score="1.00" ID="10059938">Laboratory tests </Semaphore>revealed <Semaphore x="2110173" class="Procedure" value="Leukocyte Count" score="1.00" ID="C51948">leukocyte </Semaphore><Semaphore x="3321117" class="MedDRA LLT" value="White blood cell count" score="1.00" ID="10047939">count </Semaphore>
    <Semaphore x="3321117" class="MedDRA LLT" value="White blood cell count" score="1.00" ID="10047939">of 9200/mm3, <Semaphore x="3321117" class="MedDRA LLT" value="White blood cell count" score="1.00" ID="10047939">polymorphonuclear </Semaphore>count </Semaphore>of 8500/mm3, <Semaphore x="2014841" class="Procedure" value="Hemoglobin Measurement" score="1.00" ID="C64848">hemoglobin </Semaphore>of 10.1 g/dL, <Semaphore x="2406620" class="Procedure" value="Platelet Count" score="1.00" ID="C51951"><Semaphore x="2406620" class="Procedure" value="Platelet Count" score="1.00" ID="C51951">platelet </Semaphore>count </Semaphore>of 431000/mm3, <Semaphore x="1821896" class="Procedure" value="Creatinine Measurement" score="1.00" ID="C64547">creatinine </Semaphore>of 82 umol/L, <Semaphore x="1316129" class="Medicine" value="Urea" score="0.74" ID="194669">urea </Semaphore>at 5.2 mmol/L, <Semaphore x="2536895" class="Procedure" value="Sodium Measurement" score="1.00" ID="C64809">sodium </Semaphore>of 138 mmol/L, <Semaphore x="1848940" class="Procedure" value="Dietary Protocol" score="1.00" ID="C93051">potassium </Semaphore>of 4.7 mmol/L, <Semaphore x="287292" class="Medicine" value="Calcium" score="0.74" ID="240008">calcium </Semaphore>at 2.33 mmol/L, <Semaphore x="2433448" class="Procedure" value="Protein or Enzyme Type Measurement" score="0.90" ID="C64430">protein </Semaphore>of 69 g/L, <Semaphore x="1470367" class="Procedure" value="Alkaline Phosphatase Measurement" score="1.00" ID="C64432">alkaline phosphatase </Semaphore>of 71 IU/L, <Semaphore x="1549211" class="Procedure" value="Aspartate Aminotransferase Measurement" score="1.00" ID="C64467">aspartate aminotransferase </Semaphore>of 20 IU/L, <Semaphore x="1469106" class="Procedure" value="Alanine Aminotransferase Measurement" score="1.00" ID="C64433">alanine aminotransferase </Semaphore>of 10 IU/L, and <Semaphore x="2967535" class="MedDRA LLT" value="Gamma-glutamyltransferase" score="1.00" ID="10017687">gamma glutamyltransferase </Semaphore>of 17 IU/L, <Semaphore x="2118991" class="Procedure" value="Liver Function Test" score="0.76" ID="C74954">total bilirubin </Semaphore>of 8 umol/l, <Semaphore x="2092491" class="Procedure" value="Lactate Dehydrogenase Measurement" score="1.00" ID="C64855"><Semaphore x="766926" class="Medicine" value="Lactate" score="0.74" ID="196905">lactate </Semaphore>dehydrogenase </Semaphore>of 168 IU/L and <Semaphore x="1469401" class="Procedure" value="Albumin Measurement" score="1.00" ID="C64431">albumin </Semaphore>of 37 g/L. The following day, on 01/Dec/2012, the subject received the next dose of <Semaphore x="861252" class="Medicine" value="Methotrexate" score="0.97" ID="279493">methotrexate</Semaphore>, Velve, <Semaphore x="47317" class="Medicine" value="Adriamycin" score="0.87" ID="268083">Adriamycin </Semaphore>and <Semaphore x="363530" class="Medicine" value="Cisplatin" score="0.98" ID="251595">cisplatin </Semaphore>after being postponed one week. <Semaphore x="978477" class="Medicine" value="panitumumab" score="1.00" ID="252216">Panitumumab </Semaphore>was not administered due to the persistence of <Semaphore x="2439896" class="Disease or Finding" value="Purpura" score="1.00" ID="C78787">purpura </Semaphore>on the <Semaphore x="2104605" class="AnatomicStructure" value="Leg" score="1.00" ID="C32974">legs</Semaphore>. Additional <Semaphore x="2065652" class="Procedure" value="Intervention or Procedure" score="0.58" ID="C25218">treatment </Semaphore>included <Semaphore x="527097" class="Medicine" value="Emend" score="0.49" ID="258610">Emend </Semaphore>(<Semaphore x="127207" class="Medicine" value="aprepitant" score="0.49" ID="258618">aprepitant</Semaphore>), Solupred (<Semaphore x="1081705" class="Medicine" value="prednisoLONE" score="0.49" ID="291320">prednisolone</Semaphore>) and Primperan (<Semaphore x="869037" class="Medicine" value="Metoclopramide Hydrochloride" score="0.49" ID="252249">metoclopramide hydrochloride</Semaphore>). The following day, on 02/Dec/2012 the subject was discharged from the hospital. The event was reported as ongoing at the time of this report. The subject would be readmitted on 14/Dec/2012 as stated by the investigator. Associated co morbidity included insertion and maintenance of <Semaphore x="2056709" class="Procedure" value="Infusion Procedure" score="1.00" ID="C15388">infusion </Semaphore>pump and adjustment and maintenance of CVC or catheter vascular device. The subject's last dose of <Semaphore x="978477" class="Medicine" value="panitumumab" score="1.00" ID="252216">panitumumab </Semaphore>in combination with <Semaphore x="861252" class="Medicine" value="Methotrexate" score="0.97" ID="279493">methotrexate</Semaphore>, <Semaphore x="1330202" class="Medicine" value="vinBLAStine" score="0.87" ID="196804">vinblastine</Semaphore>, <Semaphore x="507241" class="Medicine" value="DOXOrubicin" score="0.87" ID="259834">doxorubicin </Semaphore>and <Semaphore x="363530" class="Medicine" value="Cisplatin" score="0.98" ID="251595">cisplatin </Semaphore>prior to the event was on 07/Nov/2012. <Semaphore x="978477" class="Medicine" value="panitumumab" score="1.00" ID="252216">Panitumumab </Semaphore>was temporarily withheld.The investigator reported that there was a reasonable possibility that the event was related to <Semaphore x="978477" class="Medicine" value="panitumumab" score="1.00" ID="252216">panitumumab</Semaphore>.ADDITIONAL INFORMATION RECEIVED ON 02/JAN/2013: Previous <Semaphore x="2065652" class="Procedure" value="Intervention or Procedure" score="0.58" ID="C25218">treatment </Semaphore>for the condition under study included <Semaphore x="1831586" class="Procedure" value="Cystectomy" score="1.00" ID="C15217">cystectomy </Semaphore>on 25/Aug/2010 and four cycles of <Semaphore x="1447339" class="Procedure" value="Adjuvant Chemotherapy" score="1.00" ID="C15360">adjuvant <Semaphore x="2854686" class="MedDRA LLT" value="Chemotherapy" score="1.00" ID="10061758">chemotherapy </Semaphore></Semaphore>with <Semaphore x="615959" class="Medicine" value="Gemzar" score="0.49" ID="186174">Gemzar </Semaphore>(<Semaphore x="615677" class="Medicine" value="gemcitabine" score="0.49" ID="216806">gemcitabine</Semaphore>) from October 2010 to January 2011. Previous and ongoing <Semaphore x="2065652" class="Procedure" value="Intervention or Procedure" score="0.58" ID="C25218">treatment </Semaphore>included <Semaphore x="363530" class="Medicine" value="Cisplatin" score="0.98" ID="251595">cisplatin</Semaphore>. The date when subject received the first dose of <Semaphore x="978477" class="Medicine" value="panitumumab" score="1.00" ID="252216">panitumumab </Semaphore>in combination with Velbe, <Semaphore x="47317" class="Medicine" value="Adriamycin" score="0.87" ID="268083">Adriamycin </Semaphore>and <Semaphore x="363530" class="Medicine" value="Cisplatin" score="0.98" ID="251595">cisplatin </Semaphore>was updated to 07/Nov/2012. The investigator reported that <Semaphore x="2439896" class="Disease or Finding" value="Purpura" score="1.00" ID="C78787">purpura </Semaphore>cutane was <Semaphore x="2027225" class="Procedure" value="Histopathologic Examination" score="1.00" ID="C18190">grade </Semaphore>2. The <Semaphore x="1910095" class="Disease or Finding" value="Experimental Result" score="1.00" ID="C76125">results </Semaphore>of <Semaphore x="1593910" class="Procedure" value="Biopsy" score="1.00" ID="C15189">biopsy </Semaphore>with <Semaphore x="3006985" class="MedDRA LLT" value="Histology" score="1.00" ID="10062005">histology </Semaphore>and IF, <Semaphore x="1854919" class="Procedure" value="Disease Screening" score="1.00" ID="C15419">screens </Semaphore>for <Semaphore x="2053299" class="Disease or Finding" value="Infectious Disorder" score="1.00" ID="C26726">infectious and <Semaphore x="1557778" class="Disease or Finding" value="Autoimmune Disease" score="1.00" ID="C2889">autoimmune diseases </Semaphore></Semaphore>and measures of <Semaphore x="2692262" class="Procedure" value="Vitamin C Measurement" score="1.00" ID="C74903">vitamin C </Semaphore>concentrations were not available. Additionally, <Semaphore x="1910095" class="Disease or Finding" value="Experimental Result" score="1.00" ID="C76125">results </Semaphore>of immunological <Semaphore x="1854919" class="Procedure" value="Disease Screening" score="1.00" ID="C15419">screen </Semaphore>with <Semaphore x="1549600" class="Procedure" value="Assay" score="1.00" ID="C60819">assay </Semaphore>of anti neutrophil <Semaphore x="1834765" class="Disease or Finding" value="Cytoplasm Presence of Less than or Equal to Twenty Five Percent" score="1.00" ID="C104013">cytoplasmic </Semaphore><Semaphore x="2047985" class="Procedure" value="Immunology Test" score="0.58" ID="C16723">antibody (<Semaphore x="2751745" class="MedDRA LLT" value="Antineutrophil cytoplasmic antibody" score="1.00" ID="10050552">ANCA</Semaphore>), anti streptolysin O </Semaphore>(ASLO), <Semaphore x="1531531" class="Procedure" value="Anti-DNA Antibody Measurement" score="1.00" ID="C81973">anti <Semaphore x="2751991" class="MedDRA LLT" value="Antinuclear antibody" score="1.00" ID="10002807">nuclear <Semaphore x="1531531" class="Procedure" value="Anti-DNA Antibody Measurement" score="1.00" ID="C81973">antibodies</Semaphore></Semaphore>
        <Semaphore x="2912242" class="MedDRA LLT" value="DNA antibody" score="1.00" ID="10061131">
         <Semaphore x="2047985" class="Procedure" value="Immunology Test" score="0.58" ID="C16723">
          <Semaphore x="1531531" class="Procedure" value="Anti-DNA Antibody Measurement" score="1.00" ID="C81973">, <Semaphore x="1531531" class="Procedure" value="Anti-DNA Antibody Measurement" score="1.00" ID="C81973">anti DNA </Semaphore></Semaphore></Semaphore></Semaphore>antibodies</Semaphore>, <Semaphore x="2886478" class="MedDRA LLT" value="Cryoglobulinaemia" score="1.00" ID="10011474">cryoglobulinaemia</Semaphore>, C3, C4, CHso, <Semaphore x="3234162" class="MedDRA LLT" value="Rheumatoid factor" score="1.00" ID="10039079"><Semaphore x="2469227" class="Procedure" value="Rheumatoid Factor Measurement" score="1.00" ID="C74717"><Semaphore x="2047985" class="Procedure" value="Immunology Test" score="0.58" ID="C16723">rheumatoid <Semaphore x="2751991" class="MedDRA LLT" value="Antinuclear antibody" score="1.00" ID="10002807">factor</Semaphore></Semaphore>
      </Semaphore>
     </Semaphore>
    <Semaphore x="2751991" class="MedDRA LLT" value="Antinuclear antibody" score="1.00" ID="10002807">, antinuclear factor </Semaphore>and <Semaphore x="2020151" class="Disease or Finding" value="Hepatitis C Infection" score="1.00" ID="C3098"><Semaphore x="2019803" class="Disease or Finding" value="Hepatitis B Infection" score="1.00" ID="C3097">hepatitis B </Semaphore>and C </Semaphore>were also not available. The <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>of the event <Semaphore x="2439896" class="Disease or Finding" value="Purpura" score="1.00" ID="C78787">purpura </Semaphore>cutane remained as resolving. The etiology of the event <Semaphore x="2439896" class="Disease or Finding" value="Purpura" score="1.00" ID="C78787">purpura </Semaphore>cutane was not identified. The subject's last dose of investigational product prior to the event was administered during cycle 4 between 07/Nov/2012 and 09/Nov/2012. <Semaphore x="978477" class="Medicine" value="panitumumab" score="1.00" ID="252216">Panitumumab </Semaphore>was permanently discontinued at cycle 5.ADDITIONAL INFORMATION RECEIVED ON 23/Jan/2013: The investigator stated that the subject received <Semaphore x="861252" class="Medicine" value="Methotrexate" score="0.97" ID="279493">methotrexate </Semaphore>prior to the onset of the event on 26/Sep/2012, 11/Oct/2012, 25/Oct/2012 and 07/Nov/2012 and during the event on 01/Dec/2012 and 15/Dec/2012. The <Semaphore x="1883294" class="Procedure" value="End-of-Life Treatment Management" score="1.00" ID="C67359">end </Semaphore>date of the event was reported as 14/Dec/2012, however, the <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>was not provided.</narrativeincludeclinical>
				<sendercomment>Panitumumab is a high-affinity fully human immunoglobulin IgG2 monoclonal antibody that targets the human epidermal growth factor receptor leading to inhibition of EGFr activation.

The event purpura has not been documented as listed or expected in the Amgen Development Core Safety Information for product panitumumab.

Although a temporal association exists, it is not sufficient to establish, or rule out, a causal relationship between study drug and the event reported in this case. Causality is confounded by concurrent methotrexate, vinblastine, doxorubicin and cisplatin administration.

This individual case report does not change the safety profile of the product.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>